ObsEva's nolasiban meets in Phase III to improve pregnancy rates

ObsEva S.A. (NASDAQ:OBSV) reported top-line data from the the Phase III IMPLANT2 trial in 778 women showing that a single 900 mg dose of oral nolasiban

Read the full 269 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE